search
Back to results

Effect of Bovine Colostrum on Toxicity and Inflammatory Responses (CALL)

Primary Purpose

Acute Lymphoblastic Leukemia

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Bovine Colostrum
placebo
Sponsored by
Steffen Husby
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Lymphoblastic Leukemia focused on measuring Acute Lymphoblastic Leukemia, Bovine Colostrum, Inflammation, Infection, Toxicity

Eligibility Criteria

1 Year - 45 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients treated according to the Nordic Society of Pediatric Haematology and Oncology (NOPHO) ALL protocol

Exclusion Criteria:

  • Milk Allergy
  • Lactose intolerance

Sites / Locations

  • Rigshospitalet
  • Odense University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Bovine colostrum

Placebo

Arm Description

A daily supplement of bovine colostrum powder.

A daily placebo supplement consisting of whole milk powder and whey protein.

Outcomes

Primary Outcome Measures

Days with fever. Fever
Days with temperature at or above 38.5 degrees celsius.

Secondary Outcome Measures

Days in intensive care unit
Number of days treated in an intensive care unit.
Days in i.v. antibiotic treatment.
Number of days in intravenous antibiotic treatment during the intervention period.
Duration of cytopenia (neutrocytes <1,0 and platelets <20)
Proven or suspected infections
Episodes of suspected or culture positive sepsis number of documented septic events either culture proven or those treated with a course of antibiotics.
Number of blood and platelet transfusions given during the course of treatment
Number of blood and platelet transfusions given during the course of treatment
Clinical and paraclinical indices of gastrointestinal toxicity
Clinical toxicity is scored using Common Toxicity Criteria for Adverse Effects (NCI-CTCAE), WHO and oral mucositis assessment scale (OMAS) grading schemes at inclusion and weekly during the treatment period. Furthermore the patients register toxicity using the oral mucositis daily questionaire(OMDQ). Paraclinical indices are citruline, fecal calprotectin,
Serologic markers for systemic inflammation
Serum will be taken weekly. Markers will include C reactive protein (CRP), procalcitonin (PCT), soluble urokinase plasminogen activator receptor (sUPAR), plasma cytokines and receptors (IL-6, IL-8, Soluble tumour necrosis factor receptors (sTNFR1), IL-1Ra). Cytokine production in full blood cultures will be measured at day 3 and at day 24. Initial screening for a broad spectrum of cytokines will be performed in 5-10 patients. Based on these results a final panel of analyses comprising a narrower spectrum of cytokines will be determined and used for further investigation. These will include at least TNFR1, IL-1Ra, IL-6, IL-8.

Full Information

First Posted
January 9, 2013
Last Updated
July 30, 2018
Sponsor
Steffen Husby
Collaborators
University of Southern Denmark, Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT01766804
Brief Title
Effect of Bovine Colostrum on Toxicity and Inflammatory Responses
Acronym
CALL
Official Title
Effect of Bovine Colostrum on Toxicity and Inflammatory Responses During Treatment of Childhood Acute Lymphoblastic Leukaemia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
March 2013 (Actual)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Steffen Husby
Collaborators
University of Southern Denmark, Rigshospitalet, Denmark

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the present study is to evaluate the ability a colostrum containing diet to limit gastrointestinal toxicity including chemotherapy induced inflammation in children treated for acute lymphoblastic leukemia.
Detailed Description
Acute lymphoblastic leukaemia (ALL) is the most common form of childhood cancers. Cure rates are improving, but the intensity of treatment is limited by toxicity. 2-5% of patients die of treatment related complications, mostly related to therapy-induced toxicity and immune suppression. The aim of the present study is to evaluate the ability a colostrum containing diet to limit gastrointestinal toxicity including chemotherapy induced inflammation. The study is based on patients treated according to the current NOPHO protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lymphoblastic Leukemia
Keywords
Acute Lymphoblastic Leukemia, Bovine Colostrum, Inflammation, Infection, Toxicity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Randomization was computer based in blocks of eight to ensure an equal number of participants in each randomization group. The randomization scheme was generated by using the web site Randomization.com ⟨http://www.randomization.com⟩. The randomization center was located at the same hospital as one of the recruitment sites (OUH). The randomization list was sent directly and exclusively to the research secretariat in charge of treatment allocation. Bovine colostrum or the placebo supplement was provided in identical foil sachets differing only in randomization code. Participants, their treating physicians, and any individual involved in the coordination and implementation of the trial were masked to treatment allocation.
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bovine colostrum
Arm Type
Experimental
Arm Description
A daily supplement of bovine colostrum powder.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A daily placebo supplement consisting of whole milk powder and whey protein.
Intervention Type
Dietary Supplement
Intervention Name(s)
Bovine Colostrum
Other Intervention Name(s)
Colodan, Biodane-Pharma.
Intervention Description
The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Days with fever. Fever
Description
Days with temperature at or above 38.5 degrees celsius.
Time Frame
Measured two times daily and on suspicion during the intervention period, up to four weeks,
Secondary Outcome Measure Information:
Title
Days in intensive care unit
Description
Number of days treated in an intensive care unit.
Time Frame
During the 4 week intervention period
Title
Days in i.v. antibiotic treatment.
Description
Number of days in intravenous antibiotic treatment during the intervention period.
Time Frame
During the 4 week intervention period.
Title
Duration of cytopenia (neutrocytes <1,0 and platelets <20)
Time Frame
During the 4 week intervention period.
Title
Proven or suspected infections
Description
Episodes of suspected or culture positive sepsis number of documented septic events either culture proven or those treated with a course of antibiotics.
Time Frame
During the 4 week intervention period
Title
Number of blood and platelet transfusions given during the course of treatment
Description
Number of blood and platelet transfusions given during the course of treatment
Time Frame
During the 4 week intervention period.
Title
Clinical and paraclinical indices of gastrointestinal toxicity
Description
Clinical toxicity is scored using Common Toxicity Criteria for Adverse Effects (NCI-CTCAE), WHO and oral mucositis assessment scale (OMAS) grading schemes at inclusion and weekly during the treatment period. Furthermore the patients register toxicity using the oral mucositis daily questionaire(OMDQ). Paraclinical indices are citruline, fecal calprotectin,
Time Frame
At base line and weekly during the 4 week intervention period. Up to 4 weeks.
Title
Serologic markers for systemic inflammation
Description
Serum will be taken weekly. Markers will include C reactive protein (CRP), procalcitonin (PCT), soluble urokinase plasminogen activator receptor (sUPAR), plasma cytokines and receptors (IL-6, IL-8, Soluble tumour necrosis factor receptors (sTNFR1), IL-1Ra). Cytokine production in full blood cultures will be measured at day 3 and at day 24. Initial screening for a broad spectrum of cytokines will be performed in 5-10 patients. Based on these results a final panel of analyses comprising a narrower spectrum of cytokines will be determined and used for further investigation. These will include at least TNFR1, IL-1Ra, IL-6, IL-8.
Time Frame
Weekly and at day 3 and 24, up to 4 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients treated according to the Nordic Society of Pediatric Haematology and Oncology (NOPHO) ALL protocol Exclusion Criteria: Milk Allergy Lactose intolerance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mathias Rathe, MD
Organizational Affiliation
University og Southern Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steffen Husby, MD, DMSc
Organizational Affiliation
Odense University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Klaus Müller, MD, DMSc
Organizational Affiliation
Rigshospitalet, Denmark
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Peder S Wehner, MD, PhD
Organizational Affiliation
Odense University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Per T Sangild, DVSc, DMSc
Organizational Affiliation
Department of Human Nutrition, Faculty of Life Science, University of Copenhagen, Denmark
Official's Role
Study Chair
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
30861163
Citation
Rathe M, De Pietri S, Wehner PS, Frandsen TL, Grell K, Schmiegelow K, Sangild PT, Husby S, Muller K. Bovine Colostrum Against Chemotherapy-Induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Double-Blind, Placebo-Controlled Trial. JPEN J Parenter Enteral Nutr. 2020 Feb;44(2):337-347. doi: 10.1002/jpen.1528. Epub 2019 Mar 12.
Results Reference
derived
PubMed Identifier
27445347
Citation
Shen RL, Pontoppidan PE, Rathe M, Jiang P, Hansen CF, Buddington RK, Heegaard PM, Muller K, Sangild PT. Milk diets influence doxorubicin-induced intestinal toxicity in piglets. Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1;311(2):G324-33. doi: 10.1152/ajpgi.00373.2015. Epub 2016 Jul 21.
Results Reference
derived

Learn more about this trial

Effect of Bovine Colostrum on Toxicity and Inflammatory Responses

We'll reach out to this number within 24 hrs